share_log

Exicure | 8-K: Current report

Exicure | 8-K: Current report

Exicure | 8-K：重大事件
美股SEC公告 ·  09/13 16:28

Moomoo AI 已提取核心信息

On September 12, 2024, Exicure, Inc., a biotechnology company based in Chicago, entered into agreements to convert debt into equity with two of its promissory note holders. The company reached a deal with DGP Co., Ltd., its largest shareholder, to issue 237,233 shares in exchange for the full satisfaction of a $700,000 promissory note, including accrued interest. The conversion price was set at $3.00 per share. Additionally, an agreement was made with an individual note holder to issue 101,991 shares for the full satisfaction of a $300,000 promissory note, also at a conversion price of $3.00 per share. These shares will be issued unregistered under the Securities Act of 1933, in a private transaction exempt from registration requirements. In a separate event on September 13, 2024, Exicure announced that it had regained compliance with Nasdaq's minimum bid price requirement, maintaining its listing on the exchange.
On September 12, 2024, Exicure, Inc., a biotechnology company based in Chicago, entered into agreements to convert debt into equity with two of its promissory note holders. The company reached a deal with DGP Co., Ltd., its largest shareholder, to issue 237,233 shares in exchange for the full satisfaction of a $700,000 promissory note, including accrued interest. The conversion price was set at $3.00 per share. Additionally, an agreement was made with an individual note holder to issue 101,991 shares for the full satisfaction of a $300,000 promissory note, also at a conversion price of $3.00 per share. These shares will be issued unregistered under the Securities Act of 1933, in a private transaction exempt from registration requirements. In a separate event on September 13, 2024, Exicure announced that it had regained compliance with Nasdaq's minimum bid price requirement, maintaining its listing on the exchange.
2024年9月12日，总部位于芝加哥的生物技术公司exicure与两名其借款人达成协议，将债务转换为股权。该公司与其最大股东DGP公司达成协议，以每股3.00美元的价格发行了23,7233股股份，全额偿还了一张70万美元的借款票据，包括应计利息。此外，还与一位个人借款人达成协议，以每股3.00美元的价格发行了101,991股股份，全额偿还了一张30万美元的借款票据。这些股份将在1933年的证券法下以私人交易的方式发行，免于登记要求。在2024年9月13日的另一项事件中，exicure宣布已重新获得纳斯达克的最低买入价要求，并维持其在交易所的上市。
2024年9月12日，总部位于芝加哥的生物技术公司exicure与两名其借款人达成协议，将债务转换为股权。该公司与其最大股东DGP公司达成协议，以每股3.00美元的价格发行了23,7233股股份，全额偿还了一张70万美元的借款票据，包括应计利息。此外，还与一位个人借款人达成协议，以每股3.00美元的价格发行了101,991股股份，全额偿还了一张30万美元的借款票据。这些股份将在1933年的证券法下以私人交易的方式发行，免于登记要求。在2024年9月13日的另一项事件中，exicure宣布已重新获得纳斯达克的最低买入价要求，并维持其在交易所的上市。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间